Refuge Biotechnologies, Inc. logo

Refuge Biotechnologies, Inc.

Refuge Biotech is a discovery-stage therapeutic company focused on gene editing and genetic engineering of immune cells for cancer immunotherapy. Refuge is using CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) through their receptor-dCas platform to develop therapeutic cells that are programmed to make cancer-fighting decisions inside the patients body.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://refugebiotech.com
Disease Focus
STOCK CODENon Listed
Address
1505 Adams Drive, Suite D, CA 94025
Menlo Park
United States
Email
Contact Number

Refuge Biotech is a discovery-stage therapeutic company focused on gene editing and genetic engineering of immune cells for cancer immunotherapy. Refuge is using CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) through their receptor-dCas platform to develop therapeutic cells that are programmed to make cancer-fighting decisions inside the patients body.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

Refuges receptor-dCas platform, utilizes a mutated or dead Cas9 (dCas) as a targeting mechanism to enable precision CRISPR activation (CRISPRa) and CRISPR interference (CRISPRi). The cell therapies are programed to only activate CRISPRa/CRISPRi when they encounter specific sensors found on the surface of cancer cells, which delivers the treatment effect only to target cells. As a result, cell therapies have the potential to bring together multiple anti-cancer approaches in a single cell, such as repression of multiple checkpoint targets, with greater potency and reduced side effects.
Receptor-dCas platform has the potential to create highly targeted cell therapies that bring superior efficacy while overcoming limitations related to toxic side effects.

In May 2018, Refuge Biotechnologies raised $25 Mn in Series B investment, led by 3SBio and Sequoia China, with participation from investors Danhua Capital (DHVC), Sangel Capital and Ocean Pine Healthcare Fund.